in non-hospitalized COVID-19 patients, with signs it could reduce the chance of someone infected requiring hospitalization.
Schleifer additionally reiterated that the FDA has yet to approve of Regeneron's drug, and that it was reasonable for someone like Trump to have received it early. "We want everyone to be potentially able to benefit, we understand we don't make that decision — this is a decision that the FDA has to make," he said. "If you're an essential member of government and you have to conduct the people's business and the continuity of government and you can't get to a clinical trial, we'll take that into account.
Schleifer emphasized that the decision to take his company's experimental monoclonal antibody treatment isn't something that should be taken lightly, but that he understands people reaching out to inquire about compassionate use access. "This is all very complicated because it's real lives at stake," Schleifer said. "If it's someone you really care about — yes, we want to give this if we can and we help them, but of course we want to get definitive evidence. So it's a tough act to balance."
Leadership is about choices. Regeneron's CEO, Dr. Leonard Schleifer, chose to dance with the devil. Everyone else who has flirted with realDonaldTrump has learned what an asynchronous toxic relationship it turns out to be. Now, it’s Schleifer’s turn, but it was his choice.
Kudos to President 👍 victory over virus 🦠 and will win race too 👌🇺🇸
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »